Aeon Biopharma (AEON) announced feedback from the FDA following a biosimilar biological product development Type 2a meeting. During the meeting, held in January, the FDA reviewed the company’s ...
AEON Biopharma (AEON) announced that the U.S. Food and Drug Administration has scheduled a Biosimilar Biological Product Development Type 2a meeting for ABP-450 on November 19, 2025, in line with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results